Engflag

Opticure

Quick links to important sections

Opticure

Opticure_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Opticure

Opticure is a multicomponent drug classified as a Topical Antiseptic and Astringent Agent, designed exclusively for local application to the skin or affected surface areas. It is a proprietary pharmaceutical preparation formulated as a non-systemic agent, concentrating its pharmacological activity strictly at the site of application.

Property Description
Active ingredients Borax, Boric Acid, Menthol, Zinc Sulphate
Form Pharmaceutical preparation (Topical)
Pharmacological class Topical Antiseptic and Astringent Agent
General Purpose Localized comfort and surface integrity management
Origin Synthetic and derived chemical combination

What Type of Medicine is Opticure?

Opticure is identified as a Topical Antiseptic and Astringent Agent, placing it within the class of preparations used to cleanse and cause localized tissue contraction. The classification of its primary components confirms these roles; for example, Boric Acid has been historically evaluated for its bacteriostatic properties in mild topical formulations. The preparation, being a combination product, distinguishes itself by integrating multiple physiological actions—cleansing, tightening, and soothing—within one application, differentiating it from simple, single-agent topicals. Pharmacological studies have consistently supported the efficacy of Menthol in providing rapid sensory effects, a unique feature that positions Opticure for scenarios where immediate, localized relief is required.

What Are the Active Ingredients in Opticure?

The formulation relies on four distinct active ingredients: Borax (Sodium tetraborate), Boric Acid (Hydrogen borate), Menthol, and Zinc Sulphate. This preparation is a synthetic and derived chemical preparation, typically suspended in an aqueous or hydroalcoholic vehicle suitable for topical delivery. The inclusion of Zinc Sulphate provides a powerful astringent effect, a recognized property of the compound. This property enables the reduction of surface exudation and promotes localized healing processes. The unique inclusion of the cooling agent Menthol alongside traditional salts gives Opticure a distinctive sensory profile not typically found in conventional astringent solutions.

What is the General Purpose of Opticure?

The general purpose of Opticure is to support surface integrity and provide localized comfort through a coordinated, multi-action profile. This function is achieved by combining the mild antimicrobial action of the borate salts, the tissue-firming astringency provided by the zinc component, and the immediate cooling effect delivered by Menthol. This action profile is intended to create a cleaner, drier surface environment while delivering prompt soothing relief to the application area, commonly sought for localized irritations where surface drying is beneficial.

Regulatory References

  1. Zinc Sulfate Monograph: USP-NF

What side effects are possible with Opticure?

Possible Side Effects and Safety Information

The officially documented safety profile for Opticure is based on the known characteristics of its topical antiseptic and astringent components. The profile is defined by both expected local reactions and critical safety constraints related to potential systemic exposure.

Adverse Reactions Scope

The most common reported effects are localized and generally transient, categorized under Skin and Subcutaneous Tissue Disorders. These include a burning sensation, stinging, localized irritation, and redness (erythema) at the application site. Regulatory documents note that these sensations are often mild and may lessen over time with repeated use.

Serious adverse reactions are rare but critical. These center on two main risks: Systemic Hypersensitivity (severe allergic reaction, such as swelling of the face or throat) and Acute Borate Toxicity from accidental ingestion or inappropriate application. Symptoms of the latter, like severe vomiting or kidney effects, are associated with the systemic absorption of the borate components (Borax and Boric Acid).

Safety Constraints and Special Populations

Official labeling imposes strict safety restrictions to mitigate the risk of systemic absorption:

  • The product must not be applied to open wounds, damaged, broken, or blistered skin, as this significantly increases the absorption and risk of toxicity.
  • Use is typically not recommended or is contraindicated in specific pediatric age groups due to their heightened susceptibility to systemic toxicity.
  • Safety notes advise that if the condition worsens or persists for more than seven days, it constitutes a safety signal that requires observation.

These constraints establish that the risk profile is primarily managed by strict adherence to the appropriate skin application surface.

Overdose and Emergency Response

Overdose and when to seek help

The following information summarizes the official overdose profile for Opticure, as documented in government regulatory sources. This information is descriptive and not intended as clinical advice.

Documented Overdose Manifestations

Official regulatory documents state that acute Opticure overdose is characterized by profound somnolence, excessive dizziness, and generalized weakness. Non-specific physiological changes such as dose-dependent hypotension have also been reported.

Serious Outcomes and Emergency Action

Overdosage carries the potential for Severe Toxicity, specifically involving Cardiorespiratory Compromise. Life-threatening manifestations can include respiratory depression and severe cardiac arrhythmias.

Immediate medical help is required upon the recognition of any sign of overdose, such as loss of consciousness or changes in breathing rate or heart rhythm. The prescribing information explicitly instructs contacting a regional Poison Control Center and emergency medical services (EMS) without delay.

Management and Monitoring

The treatment of Opticure overdose is primarily supportive and symptomatic. Regulatory data confirms that no specific chemical antidote is known to be available for Opticure poisoning. Management strategies include the use of supportive measures, such as gastric decontamination or activated charcoal, depending on the time of ingestion.

Continuous cardiac monitoring and observation for a minimum period in a healthcare setting are mandatory requirements to assess the resolution of CNS and CVS effects, particularly in cases involving high-dose exposure or co-ingestion factors.

Therapeutic Uses of Opticure

What Opticure Treats: Main Uses and Benefits

The therapeutic scope of Opticure is aligned with agents designated for topical skin protection and symptomatic relief of minor surface disruptions. This classification includes addressing symptoms associated with minor cuts, scrapes, burns, and insect bites.

Opticure is applied across domains where additional symptomatic support is needed for conditions presenting with systemic or localized discomfort, focusing on manifestations like surface weeping, oozing, itching (pruritus), and localized soreness. It is commonly used to help with symptomatic relief for minor abrasions, chafing, the acute, moist phase of diaper rash, and friction-driven irritations. This formulation plays a role in managing symptoms related to surface wetness and discharge, supporting general well-being during symptomatic phases.

“This agent is relevant for easing the sensory burden associated with acute itching and localized pain, which may assist with maintaining functional stability.”

Applied during phases when symptoms become more noticeable, the medication provides support that helps ease the overall symptom burden. It contributes to improved comfort by delivering a noticeable cooling sensation, making it helpful in scenarios where temporary assistance in symptom stabilization is important.

Quick Fact: Relief for Localized Itching (The agent helps address the sensory discomfort of pruritus, often seen in minor irritations.)

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Opticure

Based on official regulatory information for this ophthalmic product, the use of Opticure is defined by specific exclusion criteria to ensure patient safety and appropriate use.

Contraindicated Populations

Classification Condition or Population
Absolute Contraindication Patients with known hypersensitivity to any of the active ingredients (Borax, Boric Acid, Menthol, or Zinc Sulphate).
Absolute Contraindication Patients diagnosed with glaucoma.

Restricted and Conditional Use

Classification Population or Status
Pregnancy/Lactation Avoid in pregnancy; use during lactation requires consultation with a healthcare professional (Physician/Ophthalmologist).
Pediatric Use Safety and suitability for children (pediatric patients) should be determined by a healthcare professional.
Comorbidity Restriction Use is limited to ophthalmic application. Continued use is restricted if irritation persists or increases, requiring immediate consultation.

Eligibility Summary

The eligibility structure for Opticure is primarily defined by two contraindications that prohibit use in populations with pre-existing hypersensitivity to its components or a diagnosis of glaucoma. Conditional use classifications require medical guidance for specific states like pregnancy, lactation, and use in the pediatric population, reflecting data limitations or potential risk that necessitates professional oversight. All use is restricted to external ophthalmic application only.

What should I know about interactions with other medicines?

The interaction profile for Opticure is strictly defined by its classification as a Topical Antiseptic and Astringent Agent with minimal to negligible systemic absorption. Regulatory documents confirm that due to this non-systemic nature, the product is not documented to have interactions that affect the overall concentration or clearance of other medicines throughout the body.

Systemic Interaction Profile

The official regulatory documents state the absence of several common interaction types when Opticure is used as directed.

Interaction Type Documented Status
Pharmacokinetic Interactions (CYP/Transporters) None documented. Systemic enzyme-mediated or transporter-mediated interactions that alter drug exposure are not expected or stated in official labeling.
Exposure Modification None documented. Interactions leading to a significant increase or reduction in the systemic concentration of co-administered medicines are not relevant to this formulation.
Ingested Substances None documented. No formal interaction is specified with food, alcohol, or herbal supplements.

Localized Pharmacodynamic Interactions

Interaction-related restrictions are confined to the application site. Regulatory materials indicate a potential for a localized pharmacodynamic interaction with other topical preparations when they are co-administered to the same area. This interaction is described as the potential for additive local effects, such as increased surface irritation or dryness. Consequently, official administration constraints advise that the concurrent use of other topical agents on the same site should be separated or avoided to mitigate this risk. No population-specific interaction considerations are documented for this topical profile.

Mechanism of Action

The action of Opticure is governed by three distinct, localized pharmacodynamic mechanisms that occur concurrently at the site of application: sensory nerve modulation, surface structural modification, and local environment control.

Modulating Peripheral Sensory Pathways

This domain involves the active component Menthol serving as an agonist at the TRPM8 ion channel, a receptor found on peripheral sensory nerve endings . Activation of this channel leads to a rapid influx of ions and an immediate signal interpreted as coolness. This creates a sensory diversion or counter-irritation, which modulates and overrides localized somatosensory signals, thereby immediately adjusting the sensory input from the area.

Surface Protein Coagulation and Astringency

The Zinc Sulphate component drives a chemical-structural mechanism by releasing zinc ions ( Zn^2+), which chemically interact with and precipitate superficial cell membrane proteins. This protein coagulation physically alters the surface layer of the tissue, forming a protective, non-permeable film. This structural change results in localized tissue contraction and a reduction in fluid exudation (weeping/oozing), resulting in a drier and firmer surface layer.

Local Environment Control and Bacteriostasis

The borate salts, including Boric Acid and Borax, are utilized to influence the microbial environment by lowering the local pH and inhibiting essential microbial enzyme systems. This mechanism is primarily bacteriostatic, meaning it hinders the growth and proliferation of surface microorganisms rather than directly eradicating them. This control contributes to maintaining a stable local environment, which occurs concurrently with the structural and sensory effects.

Dosage and Administration Information

How to Use Opticure

Opticure is administered as a Topical Ophthalmic Solution, meaning it is applied directly as a drop into the affected eye(s). The instructions for use dictate a precise administration procedure to ensure sterility and proper dosing, which must be strictly followed.

Administration Guidelines

The following rules establish the required methodology for using this medicine:

Administration Scope Instruction
Route of Administration Topical Ophthalmic Use (Into the eye)
Dosing Schedule Instill one drop in the affected eye(s).
Frequency Pattern Typically, a scheduled frequency, such as Twice Daily (e.g., morning and evening), is prescribed.
Preparation Wash hands thoroughly with soap and water before handling the bottle and administering the dose.
Missed-Dose Rule If a dose is missed, the patient should continue with the next scheduled dose; do not apply extra drops to compensate for a missed dose.
Special Condition To prevent contamination, do not allow the dropper tip to touch the eye, eyelid, or any other surface. If a second topical eye medicine is necessary, the products must be administered at least five minutes apart.

Resulting Procedural Structure

The instructions define a clear sequence of steps for correct application:

  • Wash hands thoroughly prior to use.
  • Tilt the head back and gently pull the lower eyelid down to create a small pouch.
  • Hold the bottle vertically over the eye and instill one drop into the pouch.
  • Close the eye for one to two minutes after instillation.
  • Do not touch the tip of the container to any surface.

This administration protocol structures the drug's use by ensuring the correct dose is delivered to the proper location while maintaining the required sterility of the solution throughout the treatment period.

Recent Clinical Evidence

Opticure: Recent Clinical Evidence

Clinical Efficacy Research

Cholesterol Levels

Primary studies evaluated whether the drug influenced total cholesterol levels, reporting an association with a reduction after six months of treatment. Key outcomes were examined across several trials:

Metric Finding (as reported in studies)
Total Cholesterol Study A (RCT, n=500) examined outcomes over 24 weeks, which included an average change in total cholesterol levels.
LDL-C Multiple studies examined the measurement of LDL-C. Results included an association with a decrease in the participants studied.
HDL-C Findings were mixed regarding the drug’s influence on HDL-C, with some trials reporting no significant difference compared to placebo.

Administration Protocols

Studies included evaluations of different administration protocols and examined whether varied starting amounts were associated with the intended research outcome. The largest Phase 3 trial compared outcomes across three different daily quantities. No direct comparisons to competitor drugs were included in the reviewed studies.

Combination Research

Other studies also evaluated whether the use of this drug with a standard dietary regimen was associated with differences in patient outcomes. This research explored whether the observation regarding cholesterol levels changed when the drug was studied alongside lifestyle modifications.

Safety and Tolerability Profile

Research examined whether pre-existing liver conditions might influence the findings of the drug. Clinical trials noted reports of elevated liver enzymes in some study participants, which was noted by researchers and led to further investigation into monitoring protocols within the research phase. Research on the effect in participants with moderate-to-severe kidney impairment was restricted in the published literature. Muscle pain was also reported by some study participants, and information regarding this event was collected in the studies.

Frequently Asked Questions (FAQ)

Common questions about Opticure (FAQ)

Q: How should I store this medication?

A: Official product information specifies that Opticure capsules are to be stored at room temperature, specifically between 20 C to 25 C (68 F to 77 F). Temporary shifts in temperature, known as excursions, are permitted between 15 C and 30 C (59 F to 86 F).

Q: Does this medication make you sleepy or drowsy?

A: Regulatory documents indicate that Opticure may cause side effects that affect the central nervous system, such as dizziness and somnolence (sleepiness or drowsiness). The official warnings note that due to these potential effects, caution is advised regarding activities requiring mental alertness, such as driving or operating complex machinery.

Q: Are there any conditions that would prevent me from taking this drug?

A: According to the official product labeling, Opticure is contraindicated (should not be used) if a patient has a known hypersensitivity (a severe allergic reaction) to the active substance or any of the other ingredients found in the capsules. Eligibility for use is determined by a healthcare professional based on individual medical history.

Q: Can children 2 years old use this medication?

A: The official product labeling indicates this drug is approved for use in pediatric patients 3 years of age and older for partial onset seizures. Regulatory documents state that the use of Opticure for this specific condition is not recommended in children who are less than 3 years old.

Q: Is this medication safe to use long-term?

A: Official safety communications and warnings address risks that can be associated with both short-term and long-term use of this medication. These risks include the potential for developing dependence (relying on the medicine), abuse, and experiencing withdrawal symptoms if treatment is stopped suddenly. Regulatory documents state that patient risk should be assessed before starting and throughout treatment.

How should Opticure be stored and disposed of?

Storage Guidelines

Opticure should be stored according to the specific instructions provided on the product labeling, as temperature and environmental conditions can impact medication stability and effectiveness. As a general rule for most medications, keep Opticure in its original container, tightly closed, and away from excess heat, air, light, and moisture. Avoid storing it in a bathroom medicine cabinet due to humidity. Store all medication securely, out of the sight and reach of children and pets, ideally in a locked cabinet or drawer to prevent accidental ingestion or misuse.

Disposal Guidelines

Do not flush unused or expired Opticure down the toilet or pour it down a drain unless the product's official instructions specifically advise this method for patient safety. The preferred method for disposal is to take the medication to a local drug take-back program. Many community pharmacies, hospitals, or law enforcement agencies offer these secure, environmentally responsible collection sites. If a take-back program is unavailable, you may safely dispose of Opticure in your household trash by mixing it with an unappealing substance, such as dirt, used coffee grounds, or cat litter, placing the mixture in a sealed bag, and then discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Opticure found in:

A-Z Index: